$PAYX — AVOID 📊 | 6 MONTHS THESIS

🧭 Conviction: MED Paychex, Inc., together with its subsidiaries, provides human capital management solutions (HCM) for payroll, employee benefits, human resources (HR), and insurance services for sm 🎯 FQ4 FY2026 (ends May) | reported Jun 24 | Rev $1.6B | Adj EPS $1.32 vs $1.31 🟢 💡 Consensus expected $1.31, actual $1.32 — a trivial beat. The market has accurately priced in modest growth. No variant view exists; the stock is fairly valued and lacks surprise potential. 🏢 Business Quality: 7 — Durable recurring revenue and high margins, but low organic growth and competitive threats limit upside./10 📊 Valuation: fair — Trailing non‑GAAP P/E 19.4x is in line with peer base multiple of 19.7x. 🔮 Catalyst: FQ1 2027 earnings (est. Sept 2026) ⚖️ Avoid — fair valuation but lopsided risk (0.3:1 reward/risk). The trivial earnings beat offers no catalyst, and the downside to peer‑level multiples is severe. 📊 Our read: AVOID. Full analysis → https://stockduty.xyz/s/PAYX0710

🧭 Conviction: MED